XJPX
7600
Market cap103mUSD
Oct 09, Last price
612.00JPY
1D
-1.13%
1Q
-35.17%
Jan 2017
-26.00%
IPO
-80.88%
Name
Japan Medical Dynamic Marketing Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Japan Medical Dynamic Marketing, Inc. is a medical device firm involved in the research, development, production, and distribution of its products throughout Japan and the United States. Its diverse portfolio includes trauma devices such as surgical nails, screws, and plates, which are implanted at fracture sites. The company also manufactures joint prostheses, designed to replace and restore the function of natural joints affected by illness or injury. Additionally, it offers spinal fixation devices for use in spinal instability surgeries, as well as artificial bone fillers for treating bone fractures, tumors, and other structural imperfections. These specialized medical solutions are supplied to healthcare professionals and hospitals. Established in 1973, the company's main office is located in Tokyo, Japan.
Key people
Koichi Kondo
Senior Executive Officer, Chief Director of Spine Business · since 2025
Naoto Sawaki
Executive Officer, Chief Director of Administration, Chief Director of SCM, Director of Human Resources and General Affairs · since 2026
Shinichi Miyata
Executive Officer, Chief Director of Pharmaceutical Affairs & Development · since 2022
Tomoyuki Yamamoto
Executive Officer, Chief Director of Sales Strategy · since 2025
Takeru Yamamoto
Executive Officer, Chief Director of Joint Business · since 2025
Yusuke Yoshida
Executive Officer, Chief Director of Business Strategy · since 2023
Yasuaki Hidaka
Senior Executive Officer, Chief Director of Trauma Business, Director · since 2025
Toshiyuki Hironaka
President, Executive President, Representative Director · since 2023
Hiromi Furushima
Independent Director · since 2025
Tomoyuki Okamura
Independent Director · since 2022
Independent Director · since 2015
Independent Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||